
    
      Participants in Australia, Colombia, Guatemala, Honduras, Israel, New Zealand, Peru, Russia,
      South Africa, and Thailand who are deriving benefit from doravirine, tenofovir, lamivudine
      are also eligible to continue receiving study drug during additional open-label extensions
      which will last for 2 years or until drug is available locally, whichever comes first.
    
  